285 related articles for article (PubMed ID: 22467094)
1. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
Boonen S; Ferrari S; Miller PD; Eriksen EF; Sambrook PN; Compston J; Reid IR; Vanderschueren D; Cosman F
J Bone Miner Res; 2012 May; 27(5):963-74. PubMed ID: 22467094
[TBL] [Abstract][Full Text] [Related]
2. Who will benefit from antiresorptive treatment (bisphosphonates)?
Papapoulos SE
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):965-73. PubMed ID: 16301190
[TBL] [Abstract][Full Text] [Related]
3. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
4. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
5. Use of bisphosphonates in the management of postmenopausal osteoporosis.
Papapoulos SE
Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
7. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
8. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.
Eriksen EF; Díez-Pérez A; Boonen S
Bone; 2014 Jan; 58():126-35. PubMed ID: 24120384
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
11. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis.
Miller PD
Expert Opin Pharmacother; 2003 Dec; 4(12):2253-8. PubMed ID: 14640924
[TBL] [Abstract][Full Text] [Related]
15. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis.
Szulc P
Clin Biochem; 2012 Aug; 45(12):907-19. PubMed ID: 22330940
[TBL] [Abstract][Full Text] [Related]
16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
[TBL] [Abstract][Full Text] [Related]
18. Recognition of women at risk for fracture and intervention with fast-acting therapies.
Derman R
Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
[TBL] [Abstract][Full Text] [Related]
19. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
20. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]